Shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) have been assigned a consensus rating of “Hold” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $6.00.
Several research analysts have weighed in on the stock. HC Wainwright set a $4.00 price objective on shares of Aptose Biosciences and gave the stock a “buy” rating in a report on Wednesday, November 15th. Zacks Investment Research raised shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Monday, December 25th. ValuEngine lowered shares of Aptose Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Canaccord Genuity set a $7.00 price objective on shares of Aptose Biosciences and gave the stock a “buy” rating in a report on Wednesday, November 15th. Finally, Roth Capital reissued a “buy” rating and set a $5.00 price objective on shares of Aptose Biosciences in a report on Monday, October 23rd.
Shares of Aptose Biosciences (APTO) opened at $3.07 on Friday. The firm has a market cap of $84.28, a price-to-earnings ratio of -4.65 and a beta of 2.55. Aptose Biosciences has a fifty-two week low of $0.78 and a fifty-two week high of $3.09.
An institutional investor recently raised its position in Aptose Biosciences stock. Acadian Asset Management LLC grew its stake in shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,421 shares of the biotechnology company’s stock after acquiring an additional 33,766 shares during the period. Acadian Asset Management LLC owned about 0.17% of Aptose Biosciences worth $100,000 at the end of the most recent quarter. 0.81% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/20/aptose-biosciences-inc-apto-receives-average-recommendation-of-hold-from-analysts.html.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.